Current Insight into the Therapeutic Potential of Phytocompounds and their Nanoparticle-Based Systems for Effective Management of Lung Cancer
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Lung cancer is the second most common cancer and the primary cause of cancer-related death in both men and women worldwide. Due to diagnosis at an advanced stage, it is associated with high mortality in the majority of patients. At present, various treatment approaches are available, such as chemotherapy, surgery, and radiotherapy, but all these approaches usually cause serious side effects like degeneration of normal cells, bone marrow depression, alopecia, extensive vomiting, etc. To overcome the aforementioned problems, researchers have focused on the alternative therapeutic approach in which various natural compounds are reported, which possessed anti-lung cancer activity. Phytocompounds exhibit their anti lung cancer activity via targeting various cell-signaling pathways, apoptosis and cell cycle arrest, and by regulating antioxidant status and detoxification. Apart from the excellent anti-cancer activity, clinical administration of phytocompounds is confined because of their high lipophilicity and low bioavailability. Therefore, researchers show their concern in the development of a stable, safe and effective approach of treatment with minimal side effects by the development of nanoparticle-based delivery of these phytocompounds to the target site. Targeted delivery of phytocompound through nanoparticles overcomes the aforementioned problems. In this article, the molecular mechanism of phytocompounds, their emerging combination therapy, and their nanoparticles-based delivery systems in the treatment of lung cancer have been discussed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 22(2022), 4 vom: 07., Seite 668-686 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fatima, Mahak [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug delivery |
|---|
| Anmerkungen: |
Date Completed 28.04.2022 Date Revised 28.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871520621666210708123750 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327841451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327841451 | ||
| 003 | DE-627 | ||
| 005 | 20231225201657.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871520621666210708123750 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1092.xml |
| 035 | |a (DE-627)NLM327841451 | ||
| 035 | |a (NLM)34238197 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fatima, Mahak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Insight into the Therapeutic Potential of Phytocompounds and their Nanoparticle-Based Systems for Effective Management of Lung Cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2022 | ||
| 500 | |a Date Revised 28.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Lung cancer is the second most common cancer and the primary cause of cancer-related death in both men and women worldwide. Due to diagnosis at an advanced stage, it is associated with high mortality in the majority of patients. At present, various treatment approaches are available, such as chemotherapy, surgery, and radiotherapy, but all these approaches usually cause serious side effects like degeneration of normal cells, bone marrow depression, alopecia, extensive vomiting, etc. To overcome the aforementioned problems, researchers have focused on the alternative therapeutic approach in which various natural compounds are reported, which possessed anti-lung cancer activity. Phytocompounds exhibit their anti lung cancer activity via targeting various cell-signaling pathways, apoptosis and cell cycle arrest, and by regulating antioxidant status and detoxification. Apart from the excellent anti-cancer activity, clinical administration of phytocompounds is confined because of their high lipophilicity and low bioavailability. Therefore, researchers show their concern in the development of a stable, safe and effective approach of treatment with minimal side effects by the development of nanoparticle-based delivery of these phytocompounds to the target site. Targeted delivery of phytocompound through nanoparticles overcomes the aforementioned problems. In this article, the molecular mechanism of phytocompounds, their emerging combination therapy, and their nanoparticles-based delivery systems in the treatment of lung cancer have been discussed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Phytocompounds | |
| 650 | 4 | |a drug delivery | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a molecular mechanism | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a therapeutic efficacy | |
| 700 | 1 | |a Iqubal, Mohammad Kashif |e verfasserin |4 aut | |
| 700 | 1 | |a Iqubal, Ashif |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Harsimran |e verfasserin |4 aut | |
| 700 | 1 | |a Gilani, Sadaf Jamal |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Md Habibur |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmadi, Amirhossein |e verfasserin |4 aut | |
| 700 | 1 | |a Rizwanullah, Md |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 22(2022), 4 vom: 07., Seite 668-686 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:4 |g day:07 |g pages:668-686 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520621666210708123750 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 4 |b 07 |h 668-686 | ||